This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://dx.doi.org/10.1097/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q56080400
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в серпні 1994 wetenschappelijk artikel im August 1994 veröffentlichter wissenschaftlicher Artikel artículu científicu espublizáu n'agostu de 1994 scientific article published on 01 August 1994
p:P577
wds:Q56080400-FDD99A7F-FFE1-4E40-9A6D-BC4BF3512D7C
wdt:P577
1994-08-01T00:00:00Z
p:P2093
wds:Q56080400-D5B42D05-F769-4F6F-B428-277311D02E51 wds:Q56080400-AF28537D-6375-4E9B-98CB-081398BF4599 wds:Q56080400-CB083356-7D36-4C9E-A02E-67A42234DC97 wds:Q56080400-AC31D189-C092-4682-A0D0-2F8FB57373A9
wdt:P2093
L Bertilsson M Jerling U Bondesson L Lindström
rdfs:label
Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine
skos:prefLabel
Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine
schema:name
Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine
p:P1476
wds:Q56080400-10AE66F8-5067-4294-8071-B4E4F4B5C63F
wdt:P1476
Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service
p:P304
wds:Q56080400-130979AC-83E7-4480-B810-7B7E03A6713D
wdt:P304
368-374
p:P31
wds:Q56080400-EC1A045C-4845-43B1-B7FB-FED5F0034042
wdt:P31
wd:Q13442814
p:P921
wds:Q56080400-93F70F50-B4D9-46BA-9280-87FB3A3CC8E1 wds:Q56080400-01CD081D-D39B-4DAF-8803-8CD3E4A8E6E5
wdt:P921
wd:Q409236 wd:Q410412
p:P698
wds:Q56080400-F07461AF-B394-4FE6-ACF4-7C0B163B44C0
wdtn:P698
n10:7974626
wdt:P698
7974626
p:P1433
wds:Q56080400-F3FB9566-064F-4C58-9499-B55413506C1F
wdt:P1433
wd:Q15724567
p:P433
wds:Q56080400-88BACF89-94D3-47E5-9D8E-D02671E6373C
p:P478
wds:Q56080400-922AF197-48CD-423E-A124-97CD32272E3F
wdt:P433
4
wdt:P478
16
p:P356
wds:Q56080400-CB483C08-64D9-4539-A621-9BB11148434B
wdtn:P356
n11:00007691-199408000-00006
wdt:P356
10.1097/00007691-199408000-00006